Psyence Biomedical (PBM) Non-Current Debt (2023)

Psyence Biomedical's (PBM) quarterly Non-Current Debt came in at $1607.8 billion in Q3 2023.

Psyence Biomedical (PBM) Non-Current Debt (2023) Analysis & Trends

Psyence Biomedical's Non-Current Debt history runs 1 years deep, the most recent figure standing at $1607.8 billion for Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 105.94 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 842.92 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Psyence Biomedical 1.56 Mn 1.56 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 1,607.77 Bn